Rheumatology News

The approval of etanercept for juvenile idiopathic arthritis in 1999 heralded a new era for children with arthritis. However, despite subsequent approvals for JIA, many patients with other types of childhood arthritis remain without options.

Prior authorization reforms, increased biosimilar access and the future of the Medicare drug price negotiation program are among the American College of Rheumatology’s top concerns in a letter recently submitted to CMS.

In part 2, we dig into the history of pulmonary hypertension. How did this strange diagnosis first get recognized, what does it have to do with cows with thick necks and urinary catheters in the heart?

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal response, according to data published in The New England Journal of Medicine.

Patients with a history of recent respiratory, skin, urogenital and gastrointestinal tract infections demonstrate a two-fold increased risk for subsequent Kawasaki disease, according to data published in RMD Open.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.

TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% compared with NSAIDs, according to data published in Arthritis & Rheumatology.

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying antirheumatic drug, according to data.

A significant number of children with juvenile idiopathic arthritis treated prior to the treat-to-target era demonstrated persistently active disease up to 5 years later, according to data from an Italian pediatric hospital.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.